volume 2, issue 8, PS458 2007
DOI: 10.1097/01.jto.0000283394.37474.cd
View full text
|
|
Share

Abstract: Background: Randomized trials and recent meta-analyses document modest survival benefits of novel two-drug chemotherapy regimens in the palliative care of patients with advanced non-small cell lung cancer (NSCLC). However, clinicians and health care policy-makers need to know whether similar survival benefits also can be achieved in the unselected NSCLC patient population as a whole. We investigated therefore the geographical and timely variation of cytotoxic drug utilization in Norway and their associations w…

Expand abstract

Search citation statements

Order By: Relevance

Citation Types

0
0
0

Paper Sections

0
0
0
0
0

Publication Types

0
0
0
0

Relationship

0
0

Authors

Journals